Since the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is responsible for an increase in IFN production, multiple JAK inhibitors (JAKi) are currently being considered in patients with SLE. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.